EMTRI

Main information

Trade name:
EMTRI VIAL INJ

Active ingredient:
Ceftriaxone

Available from:
Captab

Dosage:
1G

Pharmaceutical form:
INJ

Composition:
VIAL

Medicine domain:
Humans

Medicine type:
Allopathic drug

Documents

for the general public:
The information leaflet for this product is not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain it.

Request the information leaflet for the general public.

for healthcare professionals:
The information leaflet for this product is not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain it.

Request the information leaflet for healthcare professionals.

Localization

Available in:
India

Language:
English

Other information

Status

Source:
Central Drugs Standard Control Organization

Last update:
09-08-2016

The information leaflet for this product is not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain it.

Request the information leaflet for the general public.

Access to this document is only available to registered users.

Register now for full access

18-9-2018

Human medicines European public assessment report (EPAR): Truvada, emtricitabine / tenofovir disoproxil, Revision: 38, Authorised

Europe - EMA - European Medicines Agency

7-9-2018

Human medicines European public assessment report (EPAR): Efavirenz/Emtricitabine/Tenofovir disoproxil Mylan, efavirenz / emtricitabine / tenofovir disoproxil, Revision: 2, Authorised

Europe - EMA - European Medicines Agency

5-9-2018

Human medicines European public assessment report (EPAR): Atripla, efavirenz / emtricitabine / tenofovir disoproxil, Revision: 28, Authorised

Europe - EMA - European Medicines Agency

22-8-2018

Human medicines European public assessment report (EPAR): Eviplera, emtricitabine / rilpivirine / tenofovir disoproxil, Revision: 20, Authorised

Europe - EMA - European Medicines Agency

22-8-2018

Human medicines European public assessment report (EPAR): Stribild, elvitegravir / cobicistat / emtricitabine / tenofovir disoproxil, Revision: 18, Authorised

Europe - EMA - European Medicines Agency

17-8-2018

Human medicines European public assessment report (EPAR): Emtricitabine/Tenofovir disoproxil Krka, emtricitabine / tenofovir disoproxil, Revision: 3, Authorised

Europe - EMA - European Medicines Agency

10-8-2018

Human medicines European public assessment report (EPAR): Genvoya, elvitegravir / cobicistat / emtricitabine / tenofovir alafenamide, Revision: 16, Authorised

Europe - EMA - European Medicines Agency

6-8-2018

Human medicines European public assessment report (EPAR): Emtriva, emtricitabine, Revision: 27, Authorised

Europe - EMA - European Medicines Agency

6-8-2018

Human medicines European public assessment report (EPAR): Emtricitabine/Tenofovir disoproxil Krka d.d., emtricitabine / tenofovir disoproxil, Revision: 3, Authorised

Europe - EMA - European Medicines Agency

25-7-2018

Human medicines European public assessment report (EPAR): Genvoya, elvitegravir / cobicistat / emtricitabine / tenofovir alafenamide, Revision: 15, Authorised

Europe - EMA - European Medicines Agency

18-7-2018

Human medicines European public assessment report (EPAR): Stribild, elvitegravir / cobicistat / emtricitabine / tenofovir disoproxil, Revision: 17, Authorised

Europe - EMA - European Medicines Agency

17-7-2018

Human medicines European public assessment report (EPAR): Symtuza, darunavir / cobicistat / emtricitabine / tenofovir alafenamide, Revision: 5, Authorised

Europe - EMA - European Medicines Agency

3-7-2018

Human medicines European public assessment report (EPAR): Efavirenz/Emtricitabine/Tenofovir disoproxil Mylan, efavirenz / emtricitabine / tenofovir disoproxil, Revision: 1, Authorised

Europe - EMA - European Medicines Agency

25-6-2018

Human medicines European public assessment report (EPAR): Stribild, elvitegravir / cobicistat / emtricitabine / tenofovir disoproxil, Revision: 16, Authorised

Europe - EMA - European Medicines Agency

25-6-2018

Human medicines European public assessment report (EPAR): Odefsey, emtricitabine / rilpivirine / tenofovir alafenamide, Revision: 12, Authorised

Europe - EMA - European Medicines Agency

22-6-2018

Human medicines European public assessment report (EPAR): Biktarvy, bictegravir / emtricitabine / tenofovir alafenamide, Revision: 0, Authorised

Europe - EMA - European Medicines Agency

12-6-2018

Human medicines European public assessment report (EPAR): Atripla, efavirenz / emtricitabine / tenofovir disoproxil, Revision: 27, Authorised

Europe - EMA - European Medicines Agency

12-6-2018

Human medicines European public assessment report (EPAR): Emtriva, emtricitabine, Revision: 26, Authorised

Europe - EMA - European Medicines Agency

8-6-2018

Human medicines European public assessment report (EPAR): Descovy, emtricitabine / tenofovir alafenamide, Revision: 11, Authorised

Europe - EMA - European Medicines Agency

29-5-2018

Human medicines European public assessment report (EPAR): Stribild, elvitegravir / cobicistat / emtricitabine / tenofovir disoproxil, Revision: 15, Authorised

Europe - EMA - European Medicines Agency

24-5-2018

Human medicines European public assessment report (EPAR): Symtuza, darunavir / cobicistat / emtricitabine / tenofovir alafenamide, Revision: 4, Authorised

Europe - EMA - European Medicines Agency

23-5-2018

Human medicines European public assessment report (EPAR): Atripla, efavirenz / emtricitabine / tenofovir disoproxil, Revision: 26, Authorised

Europe - EMA - European Medicines Agency

17-5-2018

Human medicines European public assessment report (EPAR): Descovy, emtricitabine / tenofovir alafenamide, Revision: 10, Authorised

Europe - EMA - European Medicines Agency

2-5-2018

Human medicines European public assessment report (EPAR): Genvoya, elvitegravir / cobicistat / emtricitabine / tenofovir alafenamide, Revision: 14, Authorised

Europe - EMA - European Medicines Agency

4-9-2018

Efavirenz/Emtricitabine/Tenofovir disoproxil Krka (Krka d. d., Novo mesto)

Efavirenz/Emtricitabine/Tenofovir disoproxil Krka (Active substance: efavirenz / emtricitabine / tenofovir disoproxil) - Centralised - 2-Monthly update - Commission Decision (2018)5859 of Tue, 04 Sep 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4274/IB/02/G

Europe -DG Health and Food Safety

27-8-2018

Biktarvy (Gilead Sciences Ireland UC)

Biktarvy (Active substance: bictegravir / emtricitabine / tenofovir alafenamide) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)5680 of Mon, 27 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/004449/T/0001

Europe -DG Health and Food Safety

10-7-2018

Symtuza (Janssen-Cilag International NV)

Symtuza (Active substance: darunavir / cobicistat / emtricitabine / tenofovir alafenamide) - Centralised - 2-Monthly update - Commission Decision (2018)4466 of Tue, 10 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4391/WS/1312

Europe -DG Health and Food Safety

27-6-2018

Efavirenz/Emtricitabine/Tenofovir disoproxil Mylan (Mylan S.A.S.)

Efavirenz/Emtricitabine/Tenofovir disoproxil Mylan (Active substance: Efavirenz / emtricitabine / tenofovir disoproxil) - Centralised - 2-Monthly update - Commission Decision (2018)4089 of Wed, 27 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4240/IB/1/G

Europe -DG Health and Food Safety

25-6-2018

Biktarvy (Gilead Sciences International Limited)

Biktarvy (Active substance: bictegravir / emtricitabine / tenofovir alafenamide) - Centralised - Authorisation - Commission Decision (2018)4019 of Mon, 25 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4449

Europe -DG Health and Food Safety

14-6-2018

Emtricitabine/Tenofovir disoproxil Mylan (Mylan S.A.S.)

Emtricitabine/Tenofovir disoproxil Mylan (Active substance: emtricitabine / tenofovir disoproxil) - Centralised - 2-Monthly update - Commission Decision (2018)3854 of Thu, 14 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4050/IB/3/G

Europe -DG Health and Food Safety

11-6-2018

Genvoya (Gilead Sciences Ireland UC)

Genvoya (Active substance: elvitegravir / cobicistat / emtricitabine / tenofovir alafenamide) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)3763 of Mon, 11 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4042/T/45

Europe -DG Health and Food Safety

6-6-2018

Truvada (Gilead Sciences Ireland UC)

Truvada (Active substance: emtricitabine / tenofovir disoproxil fumarate) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)3690 of Wed, 06 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/594/T/148

Europe -DG Health and Food Safety

6-6-2018

Stribild (Gilead Sciences Ireland UC)

Stribild (Active substance: elvitegravir / cobicistat / emtricitabine / tenofovir disoproxil (as fumarate)) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)3691 of Wed, 06 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2574/T/93

Europe -DG Health and Food Safety

6-6-2018

Emtriva (Gilead Sciences Ireland UC)

Emtriva (Active substance: Emtricitabine) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)3693 of Wed, 06 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/533/T/123

Europe -DG Health and Food Safety

30-5-2018

Descovy (Gilead Sciences Ireland UC)

Descovy (Active substance: emtricitabine / tenofovir alafenamide) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)3471 of Wed, 30 May 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4094/T/30

Europe -DG Health and Food Safety

30-5-2018

Eviplera (Gilead Sciences Ireland UC)

Eviplera (Active substance: emtricitabine / rilpivirine (as hydrochloride) / tenofovir disoproxil (as fumarate)) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)3453 of Wed, 30 May 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2312/T/91

Europe -DG Health and Food Safety

24-5-2018

Stribild (Gilead Sciences International Limited)

Stribild (Active substance: elvitegravir / cobicistat / emtricitabine / tenofovir disoproxil (as fumarate)) - PSUSA - Modification - Commission Decision (2018)3277 of Thu, 24 May 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2574/PSUSA/10082/201708

Europe -DG Health and Food Safety

18-5-2018

Odefsey (Gilead Sciences Ireland UC)

Odefsey (Active substance: emtricitabine / rilpivirine / tenofovir alafenamide) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)3152 of Fri, 18 May 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4156/T/30

Europe -DG Health and Food Safety

27-4-2018

Pending EC decision: Biktarvy, bictegravir / emtricitabine / tenofovir alafenamide, Opinion date: 26-Apr-2018

Europe - EMA - European Medicines Agency

20-2-2018

Human medicines European public assessment report (EPAR): Efavirenz/Emtricitabine/Tenofovir disoproxil Krka, efavirenz / emtricitabine / tenofovir disoproxil, Revision: 0, Authorised

Europe - EMA - European Medicines Agency

21-11-2017

Human medicines European public assessment report (EPAR): Efavirenz/Emtricitabine/Tenofovir disoproxil Mylan, efavirenz / emtricitabine / tenofovir disoproxil, Revision: 0, Authorised

Europe - EMA - European Medicines Agency